Dr. Wade B. May, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in New Orleans (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 3,115
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: Louisiana State University School of Medicine in New Orleans
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
LA license 200957
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ochsner Lafayette General Medical Center Lafayette, LA
- Ochsner St Martin Hospital Breaux Bridge, LA
- Acadia General Hospital Crowley, LA
- Ochsner American Legion Hospital Jennings, LA
- Abrom Kaplan Memorial Hospital Kaplan, LA
Medical groups
- Lafayette Health Ventures Inc (309 clinicians)
- Cardiovascular Institute of the South, LLC (146 clinicians)
- Lafayette General Medical Center Inc (81 clinicians)
- Ochsner American Legion Hospital, LLC (31 clinicians)
- St Martin Hospital Inc (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 3,115
- Services billed
- 24,125
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session | 4,778 | 252 |
| Intensive cardiac rehabilitation; with or without continuous ecg monitoring; without exercise, per session | 4,460 | 243 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 2,299 | 1,742 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,567 | 986 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,318 | 1,141 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 764 | 751 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 612 | 65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 534 | 399 |
| Injection, regadenoson, 0.1 mg | 496 | 124 |
| Ultrasound of both sides of head and neck blood flow | 334 | 328 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Lafayette, LA | 2,531 |
| Atorvastatin Calcium Other prescribers in Lafayette, LA | 2,333 |
| Metoprolol Succinate Other prescribers in Lafayette, LA | 2,327 |
| Amlodipine Besylate Other prescribers in Lafayette, LA | 2,172 |
| Ezetimibe Other prescribers in Lafayette, LA | 1,887 |
| Carvedilol Other prescribers in Lafayette, LA | 1,533 |
| Eliquis (apixaban) Other prescribers in Lafayette, LA | 1,372 |
| Furosemide Other prescribers in Lafayette, LA | 1,200 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Lafayette, LA | 889 |
| Lisinopril Other prescribers in Lafayette, LA | 840 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 23 payments worth $566 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $234 |
|---|---|
| Kestra Medical Technology Services, Inc. | $57.51 |
| Amgen Inc. | $54.98 |
| Philips North America LLC | $44.79 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $36.07 |
| E.r. Squibb & Sons, L.l.c. | $31.15 |
| Merck Sharp & Dohme LLC | $30.96 |
| Cleerly, Inc. | $24.75 |
| Food and Beverage | $566 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $26,382 in research payments for these studies, mostly to the institutions running them.
- Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation - A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a)
Novartis Pharmaceuticals Corporation - A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.